Riskpilot← Back to searchSign inGet full accessAsarina Pharma AB (publ)
ABIn liquidationOrg 5566980750Neptunigatan 42Research and experimental development on natural sciences and engineering · NACE 7210Est. 20060 employees
Revenue 2024
SEK 0
EBITDA margin
—
+70% vs 2023
Equity ratio
54.7%
Financial strength
Net profit 2024
SEK 5,5M
+104% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -1,1M | +70% |
| Net profit | SEK 5,5M | +104% |
| Total assets | SEK 9,7M | +328% |
| Equity | SEK 5,3M | +3088% |
| Employees | 0 | — |
Legal name
Asarina Pharma AB (publ)
Org number
5566980750
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6 februari 2006
Share capital
SEK 5 660 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Föremålet för bolagets verksamhet är forskning, utveckling, tillverkning och försäljning av läkemedel samt bedriva annan därmed förenlig verksamhet.
Address
Neptunigatan 42
Email
johan.klavus@tragardh.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −7 846 | −3 428 | −4 835 | −3 748 | −1 141 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −7 846 | −3 428 | −4 835 | −3 748 | −1 141 |
| Net financials | −1 161 | 70 | −237 390 | −241 787 | 6 636 |
| Profit before tax | −8 329 | −3 358 | −123 568 | −124 618 | 5 496 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −8 329 | −3 358 | −123 568 | −124 618 | 5 496 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 248 404 | 249 074 | 125 299 | 2 272 | 9 732 |
| Equity | 245 156 | 242 169 | 124 441 | −178 | 5 319 |
| Long-term debt | 0 | 40 | 40 | 0 | 0 |
| Short-term debt | 3 248 | 6 865 | 818 | 2 449 | 4 413 |
| Total debt | 3 248 | 6 905 | 858 | 2 449 | 4 413 |
EBITDA margin
-114100000.0%
This company
15.8%
Market median
-722151999% vs market
20202024
Equity ratio
54.7%
This company
38.2%
Market median
+43% vs market
20202024
Return on equity
103.3%
This company
18.4%
Market median
+461% vs market
20202024
Net profit margin
549600000.0%
This company
8.1%
Market median
+6785185085% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.83×
This company
0.62×
Market median
+34% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JD Chief Auditor | Chief Auditor | 2022 |
HJ Liquidator | Liquidator | 2025 |
| Former (4) | ||
BS Chief Auditor | Chief Auditor | 2020 – 2021 |
JD External Signatory | External Signatory | 2020 – 2025 |
OC Chief Auditor | Chief Auditor | 2021 – 2022 |
PN Chief Executive Officer | Chief Executive Officer | 2020 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Former (7) | ||
| Chairman | 2020 – 2025 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2020 – 2025 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2025 | |
| Board of Directors | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Asarina Pharma AB (publ) (this company)
ASARINA PHARMA APSAsarina Pharma ApsBoard members of Asarina Pharma AB (publ) also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Daniel Åkeborg | Chief Auditor | 0 companies |
| Börje Stefan Andersson Berglund | Chief Auditor | 0 companies |
| Jakob Dynnes Hansen | External Signatory | 0 companies |
| Ola Christopher Carelius Larsmon | Chief Auditor | 0 companies |
| Hans Johan Henrik Klåvus | Liquidator | 0 companies |
| Peter Nordkild | Chief Executive Officer | 0 companies |
| Paul Karl Mikael de Potocki | Chairman | 0 companies |
| Miroslav Reljanovic | Board of Directors | 0 companies |
| André Louis Sam Ulmann | Board of Directors | 0 companies |
| Erin Elizabeth Gainer | Board of Directors | 0 companies |
| Mathieu William Simon | Board of Directors | 0 companies |
| Marianne Kock | Board of Directors | 0 companies |
| Hans Vidar Wendel-Hansen | Board of Directors | 0 companies |